Department of Biologics, BeiGene (Beijing) Co. Ltd, Beijing, China.
Department of Molecular Science, BeiGene (Beijing) Co. Ltd, Beijing, China.
MAbs. 2023 Jan-Dec;15(1):2215364. doi: 10.1080/19420862.2023.2215364.
Aspartic acid (Asp) isomerization is a spontaneous non-enzymatic post-translation modification causing a change in the structure of the protein backbone, which is commonly observed in therapeutic antibodies during manufacturing and storage. The Asps in Asp-Gly (DG), Asp-Ser (DS), and Asp-Thr (DT) motifs in the structurally flexible regions, such as complementarity-determining regions (CDRs) in antibodies, are often found to have high rate of isomerization, and they are considered "hot spots" in antibodies. In contrast, the Asp-His (DH) motif is usually considered a silent spot with low isomerization propensity. However, in monoclonal antibody mAb-a, the isomerization rate of an Asp residue, Asp55, in the aspartic acid-histidine-lysine (DHK) motif present in CDRH2 was found to be unexpectedly high. By determining the conformation of DHK motif in the crystal structure of mAb-a, we found that the Cgamma of the Asp side chain carbonyl group and the back bone amide nitrogen of successor His were in proximal contact, which facilitates the formation of succinimide intermediate, and the +2 Lys played an important role in stabilizing such conformation. The contributing roles of the His and Lys residues in DHK motif were also verified using a series of synthetic peptides. This study identified a novel Asp isomerization hot spot, DHK, and the structural-based molecular mechanism was revealed. When 20% Asp55 isomerization in this DHK motif occurred in mAb-a, antigen binding activity reduced to 54%, but the pharmacokinetics in rat was not affected significantly. Although Asp isomerization of DHK motif in CDR does not appear to have a negative impact on PK, DHK motifs in the CDRs of antibody therapeutics should be removed, considering the high propensity of isomerization and impact on antibody activity and stability.
天冬氨酸(Asp)异构化是一种自发的非酶翻译后修饰,导致蛋白质骨架结构发生变化,这种变化在治疗性抗体的制造和储存过程中很常见。在结构上具有柔性的区域(如抗体的互补决定区(CDR))中的Asp-Gly(DG)、Asp-Ser(DS)和 Asp-Thr(DT)基序中的Asp 通常会发生高异构化率,被认为是抗体中的“热点”。相比之下,Asp-His(DH)基序通常被认为是低异构化倾向的“静默点”。然而,在单克隆抗体 mAb-a 中,发现 CDRH2 中 Asp-His-Lys(DHK)基序中的一个 Asp 残基(Asp55)的异构化速率出乎意料地高。通过确定 mAb-a 晶体结构中 DHK 基序的构象,我们发现 Asp 侧链羰基和后继 His 的骨架酰胺氮处于近端接触,这有利于形成琥珀酰亚胺中间体,而+2 Lys 在稳定这种构象中起着重要作用。使用一系列合成肽也验证了 DHK 基序中 His 和 Lys 残基的贡献作用。本研究确定了一个新的 Asp 异构化热点 DHK,并揭示了基于结构的分子机制。当 mAb-a 中 20%的 Asp55 发生异构化时,抗原结合活性降低至 54%,但在大鼠中的药代动力学没有受到显著影响。尽管 DHK 基序在 CDR 中的 Asp 异构化似乎对 PK 没有负面影响,但考虑到异构化的高倾向以及对抗体活性和稳定性的影响,抗体治疗药物的 CDR 中的 DHK 基序应该被去除。